HALIFAX, July 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today
that it received a Notice on Grant of Patent Right For Invention (equivalent
to the Notice of Allowance in the United States) from the State Intellectual
Property Office (SIPO) of the People's Republic of China for its rapid
diagnostic device and assay (Chinese Patent Application No. 02819646.5). The
novel invention is the rapid flow-through technology (RFT) platform, the core
product engine upon which the company has built its successful line of rapid
tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's
IP "triple crown" along with similar patents awarded in the United States
(Patent Application No. 10/163,675) and the European Union (European Patent
No. EP1417489).
